Detection of Donor Specific Anti-HLA Antibodies Using Antibody Monitoring System.
- Author:
Eun Jee OH
1
;
Yeon Joon PARK
;
Jin Young KIM
;
Chul Woo YANG
;
Dong Goo KIM
;
In Sung MOON
Author Information
1. Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Transplantation;
Donor-specific HLA antibody;
Panel reactive antibody (PRA);
Flowcytometric crossmatch;
Antibody monitoring system (AMS)
- MeSH:
Antibodies*;
Enzyme-Linked Immunosorbent Assay;
Histocompatibility Antigens Class II;
HLA Antigens;
Humans;
Immunoglobulin G;
Sensitivity and Specificity;
Tissue Donors*;
Transplantation
- From:The Journal of the Korean Society for Transplantation
2006;20(1):63-68
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The antibody monitoring system (AMS, GTI Inc.) is a solid phase ELISA crossmatch test for the detection of IgG antibody to the donor-specific solubilized HLA class I and class II antigens. The objective of this study was to compare the results of AMS assay with donor specific anti-HLA IgG antibodies (DS-HLA Abs), as determined by ELISA-PRA and flowcytometric crossmatch test (FCXM). METHODS: A total of 132 sera were tested for the presence of DS-HLA Abs by ELISA-EIA, FCXM and AMS assay. RESULTS: DS-HLA Abs were determined in 41 serum samples by an ELISA-PRA panel and FCXM. There was a significant degree of concordance (84.8%) between the results from the FCXM and AMS (P<0.001). The sensitivity, specificity, the positive predictive value and the negative predictive value of AMS assay to detect DS-HLA Abs was 90.2%, 93.4%, 86.0%, 95.5%, respectively. The AMS is a simple, objective test and it has several advantages over the cell-based crossmatch test such as elimination of non-HLA antibody reactivity, elimination of the non-donor specific antibody reactivity, no need for viable cells, and the donor's HLA antigens can be prepared in advance. CONCLUSION: This study suggests that AMS may be useful as a supportive crossmatch test or as a monitoring test after transplantation for detecting class I and/or class II DS-HLA Abs.
